Cerliponase Alfa News
Cerliponase Alfa currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Cerliponase Alfa with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Brineura is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency
- Evidence level: L5
- Predicted indications (20):
- Scheie syndrome (100.0%)
- Hurler syndrome (100.0%)
- lysosomal storage disease with skeletal involvement (100.0%)
- cholesteryl ester storage disease (99.9%)
- Gaucher disease (99.9%)
- familial encephalopathy with neuroserpin inclusion bodies (99.9%)
- infantile neuronal ceroid lipofuscinosis (99.9%)
- Wolman disease with hypolipoproteinemia and acanthocytosis (99.9%)
- myoclonic epilepsy, juvenile, susceptibility to (99.9%)
- proximal myopathy with extrapyramidal signs (99.9%)
- autosomal ichthyosis syndrome with fatal disease course (99.9%)
- Wolman disease (99.9%)
- adolescent/adult-onset epilepsy syndrome (99.9%)
- Tay-Sachs disease (99.9%)
- adolescence-adult electroclinical syndrome (99.9%)
- growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant (99.9%)
- adult Krabbe disease (99.9%)
- Sanfilippo syndrome (99.8%)
- lysosomal acid lipase deficiency (99.8%)
- skeletal muscle disease (99.8%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.